| Literature DB >> 28176474 |
Usman Mahmood1, Nicole Isbel1, Peter Mollee2, Andrew Mallett3, Sridevi Govindarajulu4, Ross Francis1.
Abstract
Haemolytic uraemic syndrome is a rare condition with an overall incidence of one to two cases in a population of 100 000 and approximately 10% of these cases are classified as atypical. Atypical haemolytic uraemic syndrome (aHUS) is a thrombotic microangiopathy (TMA) characterized by microangiopathic haemolytic anaemia (MAHA), thrombocytopenia and acute kidney injury. aHUS can be genetic, acquired or idiopathic (negative genetic screening and no environmental triggers). We describe a case of aHUS triggered by monoclonal gammopathy of renal significance (MGRS) successfully treated with plasmapheresis and a bortezomib-based chemotherapy regimen, resulting in marked improvement in renal function and other markers of haemolysis. This patient has been in remission for more than 2 years currently.Entities:
Keywords: Acute kidney injury; Atypical haemolytic uraemic syndrome; Bortezomib; Complement; Membranoproliferative glomerulonephritis; Monoclonal gammopathy of renal significance; Thromobotic microangiopathy
Mesh:
Year: 2017 PMID: 28176474 DOI: 10.1111/nep.12934
Source DB: PubMed Journal: Nephrology (Carlton) ISSN: 1320-5358 Impact factor: 2.506